Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, PK and PD of RG002C0106 in Healthy Participants
NCT07902245Phase 1Not yet recruiting
- Sponsor
- Rigerna Therapeutics
- Start
- Dec 2026
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing RG002C0106 injection with Placebo (2 arms). Primary endpoint: Incidences of adverse events and serious adverse events at 169 days. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
RG002C0106
Beyond the preview
Go deeper on NCT07902245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07902245.